<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, the drug was evaluated for its effectiveness and safety as an add-on treatment in patients with COVID-19 pneumonia. Meplazumab was found to speed up the recovery of patients with pneumonia associated with COVID-19 infection with a favorable safety profile [
 <xref rid="B87-pharmaceuticals-13-00096" ref-type="bibr">87</xref>]. The findings of this study support the carrying out of a large-scale investigation of meplazumab as a possible treatment for COVID-19 pneumonia.
</p>
